Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

Starting Monday, the lowest dose vial will cost $299 a month for those who pay cash, Lilly said in a statement, a discount of about $50. The next higher dose will cost $399 a month, roughly 20% less than the previous self-pay price. Lilly isn’t changing the price of higher doses, which are sold for $499 a month.

It’s the latest move in a price war with Denmark’s Novo Nordisk, which is making it significantly less expensive for people to start the blockbuster medicines. Novo cut its cash-pay prices in November. Introductory doses for its Ozempic and Wegovy are now $199 for the first two months on the NovoCare direct-to-consumer portal, th

See Full Page